AIM: To evaluate the tolerability and toxicity of PCI in patients with NSCLC. BACKGROUND: Prophylactic cranial irradiation (PCI) is a standard treatment for patients with small cell lung cancer. There are data showing a decreasing ratio of brain metastases after PCI for non-small cell lung cancer (NSCLC-non small cell lung cancer) patients but, so far, there is no evidence for increasing overall survival. The main concern in this setting is the tolerance and toxicity of the treatment. MATERIALS AND METHODS: From 1999 to 2007, 50 patients with NSCLC treated with radical intent underwent PCI (30 Gy in 15 fractions). Mean follow-up was 2.8 years. The tolerability and hematological toxicity were evaluated in all patients, a part of participants had done neuropsychological tests, magnetic resonance imaging with (1)H nuclear magnetic resonance spectra, and estimation of pituitary function. RESULTS: During follow-up, 20 patients developed distant metastases, 4-brain metastases. Fourteen (30%) patients had acute side effects: (headache, nausea, erythema of the skin). The symptoms did not require treatment breaks. Six patients complained of late side effects (vertigo, nausea, anxiety, lower extremity weakness, deterioration of hearing and olfactory hyperesthesia). Hematological complications were not observed. Testosterone levels tended to decrease (p = 0.062). Visual-motor function deteriorated after treatment (p < 0.059). Performance IQ decreased (p < 0.025) and the difference between performance IQ and verbal IQ increased (p < 0.011). Degenerative periventricular vascular changes were observed in two patients. Analysis of the spectroscopic data showed metabolic but reversible alterations after PCI. CONCLUSION: PCI in the current series was well tolerated and associated with a relatively low toxicity.
AIM: To evaluate the tolerability and toxicity of PCI in patients with NSCLC. BACKGROUND: Prophylactic cranial irradiation (PCI) is a standard treatment for patients with small cell lung cancer. There are data showing a decreasing ratio of brain metastases after PCI for non-small cell lung cancer (NSCLC-non small cell lung cancer) patients but, so far, there is no evidence for increasing overall survival. The main concern in this setting is the tolerance and toxicity of the treatment. MATERIALS AND METHODS: From 1999 to 2007, 50 patients with NSCLC treated with radical intent underwent PCI (30 Gy in 15 fractions). Mean follow-up was 2.8 years. The tolerability and hematological toxicity were evaluated in all patients, a part of participants had done neuropsychological tests, magnetic resonance imaging with (1)H nuclear magnetic resonance spectra, and estimation of pituitary function. RESULTS: During follow-up, 20 patients developed distant metastases, 4-brain metastases. Fourteen (30%) patients had acute side effects: (headache, nausea, erythema of the skin). The symptoms did not require treatment breaks. Six patients complained of late side effects (vertigo, nausea, anxiety, lower extremity weakness, deterioration of hearing and olfactory hyperesthesia). Hematological complications were not observed. Testosterone levels tended to decrease (p = 0.062). Visual-motor function deteriorated after treatment (p < 0.059). Performance IQ decreased (p < 0.025) and the difference between performance IQ and verbal IQ increased (p < 0.011). Degenerative periventricular vascular changes were observed in two patients. Analysis of the spectroscopic data showed metabolic but reversible alterations after PCI. CONCLUSION: PCI in the current series was well tolerated and associated with a relatively low toxicity.
Entities:
Keywords:
MRS – 1H nuclear magnetic resonance spectra; Non-small cell lung cancer (NSCLC); Prophylactic cranial irradiation (PCI); Testosterone level; Toxicity of radiotherapy
Authors: R Tarnawski; L Michalecki; S Blamek; L Hawrylewicz; T Piotrowski; K Slosarek; R Kulik; B Bobek-Billewicz Journal: Neoplasma Date: 2011 Impact factor: 2.575
Authors: Alexander Sun; Kyounghwa Bae; Elizabeth M Gore; Benjamin Movsas; Stuart J Wong; Christina A Meyers; James A Bonner; Steven E Schild; Laurie E Gaspar; Jeffery A Bogart; Maria Werner-Wasik; Hak Choy Journal: J Clin Oncol Date: 2010-12-06 Impact factor: 44.544
Authors: Berend J Slotman; Murielle E Mauer; Andrew Bottomley; Corinne Faivre-Finn; Gijs W P M Kramer; Elaine M Rankin; Michael Snee; Matthew Hatton; Pieter E Postmus; Laurence Collette; Suresh Senan Journal: J Clin Oncol Date: 2008-12-01 Impact factor: 44.544
Authors: A H Russell; T E Pajak; H M Selim; J C Paradelo; K Murray; P Bansal; J D Cooper; S Silverman; J A Clement Journal: Int J Radiat Oncol Biol Phys Date: 1991-08 Impact factor: 7.038
Authors: R Komaki; C B Scott; R Byhardt; B Emami; S O Asbell; A H Russell; M Roach; M B Parliament; L E Gaspar Journal: Int J Radiat Oncol Biol Phys Date: 1998-09-01 Impact factor: 7.038
Authors: Oscar Arrieta; Cynthia Villarreal-Garza; Jesús Zamora; Mónika Blake-Cerda; María D de la Mata; Diego G Zavala; Saé Muñiz-Hernández; Jaime de la Garza Journal: Radiat Oncol Date: 2011-11-25 Impact factor: 3.481
Authors: Margarita Martin; Raúl Hernanz; Carmen Vallejo; Leonardo Guerrero; Xabier Mielgo; Ana Lopez; Juan Carlos Trujillo-Reyes; Felipe Couñago Journal: Rep Pract Oncol Radiother Date: 2022-07-29